DiaMedica TherapeuticsDMAC -0.45%31 3-1 Month Momentum % is -11.02% as of Jul. 11, 2026. GuruFocus rates DMAC with a GF Score™ of 31/100. The stock has 2 warning signs investors should review. Among 1,385 Biotechnology companies, DiaMedica Therapeutics ranks worse than 53.36% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-07-11), DiaMedica Therapeutics's 3-1 Month Momentum % is -11.02%.
The industry rank for DiaMedica Therapeutics's 3-1 Month Momentum % or its related term are showing as below:
DMAC's 3-1 Month Momentum % is ranked worse than 53.36% of 1385
companies
in the Biotechnology industry
Industry Median: -10.98
vs DMAC: -11.02
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
DiaMedica Therapeutics 3-1 Month Momentum % Related Terms
DMAC vs PRLD, RCKT, TENX: 3-1 Month Momentum % Comparison
For the Biotechnology subindustry, DiaMedica Therapeutics's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
DiaMedica Therapeutics 3-1 Month Momentum % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, DiaMedica Therapeutics's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where DiaMedica Therapeutics's 3-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DiaMedica Therapeutics (DMAC) has a 3-1 Month Momentum % of -11.02% as of Jul. 11, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on DiaMedica Therapeutics and its competitors. According to the industry distribution chart, DiaMedica Therapeutics ranks #739 out of 1385 companies in the Biotechnology industry, placing it in the top 53.4%.
Is DiaMedica Therapeutics' 3-1 Month Momentum % too high?
DiaMedica Therapeutics' current 3-1 Month Momentum % is -11.02%. Based on the distribution chart, DiaMedica Therapeutics ranks #739 out of 1385 companies in the Biotechnology industry, which is below the industry midpoint. Overall, DiaMedica Therapeutics has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does DiaMedica Therapeutics' 3-1 Month Momentum % compare to PRLD and RCKT?
According to the Biotechnology industry distribution chart, DiaMedica Therapeutics ranks #739 out of 1385 companies for 3-1 Month Momentum %. This places DiaMedica Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
A good 3-1 Month Momentum % depends on the Biotechnology industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on DiaMedica Therapeutics and its competitors. DiaMedica Therapeutics's current 3-1 Month Momentum % is -11.02%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DiaMedica Therapeutics stock overvalued right now?
DiaMedica Therapeutics (DMAC) has a current 3-1 Month Momentum % of -11.02%. The current 3-1 Month Momentum % is -11.02%. DiaMedica Therapeutics' overall GF Score™ is 31/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For DiaMedica Therapeutics (DMAC), the current 3-1 Month Momentum % is -11.02% as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.
31GF Score
Get the complete analysis for DMAC
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DMAC has been successfully added to your 